anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 21,331-21,360
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

21,331-21,360 of 26,550

filter-aware
05
The slide uses a molecular visualization of an antibody to illustrate the two functional arms of a T-cell engager.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide features a scientific poster as an embedded image, which contains multiple charts and technical data points.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
07
The slide features a thumbnail of a scientific poster titled 'Breaking barriers to access intracellular targets with T-cell engagers'.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a dark overlay on a photo of people working, with a prominent callout box for the key achievement.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Evidence & Proof1 hit
09
The slide uses a dark overlay on a professional photo to emphasize the text.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Evidence & Proof1 hit
10
Uses a three-pillar strategic framework for capital allocation.AbCellera | Results Presentation Deck | 18 slides · AbCellera
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
03
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
04
The slide uses a Gantt-style chart to represent clinical trial progress.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
05
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
ADA stands for Anti-Drug Antibodies.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a timeline-based progression of symptoms to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
Includes box plots for arginine levels and bar charts for patient normalization rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
19
The slide uses a heatmap to display individual patient outcomes across four metrics (pArg, GMFM-E, 2MWT, GMFM-D).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
20
The slide presents clinical trial safety data comparing Pegzilarginase to a placebo group.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
23
The slide presents a standard quarterly financial comparison (P&L summary) and balance sheet highlights.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Before After1 hit
26
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Development1 hit
13
Includes disclosure regarding inability to provide full GAAP reconciliation for future guidance.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Development1 hit
14
The slide provides a detailed breakdown of adjustments for operating expenses, operating loss, loss before income taxes, net loss, and loss per share.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Development1 hit
15
The slide presents two separate tables comparing financial data across different periods (2021-2023).jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Development1 hit
16
Data as of March 31, 2023.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Resolution1 hit
17
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Resolution1 hit